TNF and melanoma: These results led us to demonstrate the benefit of using TNF-blocking antibodies to potentiate the therapeutic effects of anti-PD-1 in melanoma-bearing mice going from 20% tumor rejection with anti-PD-1 alone to 75% with the combination therapy [6, 7].